The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer: The Latest Breakthroughs in Immunotherapy for GU Cancers CME Available: https://auau.auanet.org/node/39543 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Identify the newest immunotherapy drugs approved for prostate, bladder, and kidney cancer, including immune checkpoint inhibitors and other novel immunotherapies. 2. Discuss the clinical evidence supporting the use of these immunotherapy drugs in prostate, bladder, and kidney cancer, including data from pivotal clinical trials, response rates, and survival outcomes. 3. Evaluate the safety profile and potential immune-related adverse events associated with the newest immunotherapy drugs in GU cancers. ACKNOWLEDGEMENTS: Support provided by independent educational grants from:  AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC  Lantheus Medical Imaging Merck & Co., Inc.